Robert J. Wenzel
@Aisling Capital Management Lp
Latest period2024 - Q3ReportedManaged Assets$261.072MTotal holdings16
Assets growth rate13%Assets growth rate (2-Q avg)-4.4%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Aisling Capital Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 16 positions.
Assets under management
The assets under management (AUM) of Aisling Capital Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 261.072M in assets, with a quarterly growth rate of 13% and a 2-quarter average growth rate of -4.4%. The portfolio is managed by Robert J. Wenzel, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
BBIOBridgebio Pharma Inc. (bbio)
| 59.18% | $154.494M 6.068M shares@ $25.47 avg price | |
VRNAVerona Pharma Plc (vrna)
| 12.3% | $32.089M 1.115M shares@ $28.77 avg price | |
SNDXSyndax Pharmaceuticals, Inc. (sndx)
| 7.56% | $19.731M 1.025M shares@ $19.25 avg price | |
BCAXBicara Therapeutics Inc. (bcax)
| 5.56% | $14.49M 568,919 shares@ $25.48 avg price | New Position |
BMEABiomea Fusion Inc (bmea)
| 3.1% | $8.067M 798,757 shares@ $10.11 avg price | |
GLUEMonte Rosa Therapeutics Inc (glue)
| 2.99% | $7.803M 1.472M shares@ $5.3 avg price | |
CMPSCompass Pathways Plc (cmps)
| 2.33% | $6.076M 964,500 shares@ $6.3 avg price | |
NUVBNuvation Bio Inc. (nuvb)
| 2.23% | $5.819M 2.541M shares@ $2.3 avg price | |
PSTXPoseida Therapeutics Inc. (pstx)
| 1.15% | $2.984M 1.043M shares@ $2.87 avg price | |
TECXTectonic Therapeutic Inc (tecx)
| 0.98% | $2.55M 84,148 shares@ $30.3 avg price |